The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1351
November 15, 2010
View Complete Issue         Table of Contents 2019 
Dabigatran Etexilate (Pradaxa) - A New Oral Anticoagulant
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dabigatran Etexilate (Pradaxa) - A New Oral Anticoagulant
November 15, 2010 (Issue: 1351)
The FDA has approved the oral direct thrombin inhibitor dabigatran (da big’ a tran) etexilate (Pradaxa – Boehringer Ingelheim) for prevention of thromboembolic stroke in patients with non-valvular atrial fibrillation. It has been available in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Dabigatran Etexilate (Pradaxa) - A New Oral Anticoagulant
Article code: 1351a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.